Simian immunodeficiency virus macaque models of HIV latency

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 57-61

  Deere, Jesse D ^a   Schinazi, Raymond F ^b   North, Thomas W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Latency; Nonhuman primate model of AIDS therapy; RT SHIV; Simian immunodeficiency virus; Viral persistence

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; RALTEGRAVIR; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACACA; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TISSUE DISTRIBUTION; VIRUS LATENCY; VIRUS REPLICATION; ANIMAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENICITY; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LATENCY;

EID: 79954449481     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32834086ce     Document Type: Article

References (41)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
2. Finzi D, HermankovaM, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300. (Pubitemid 27495742)
3. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873. (Pubitemid 28350581)
4. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197. (Pubitemid 27518498)
5. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188. (Pubitemid 27209433)
6. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517. (Pubitemid 29220209)
7. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother 2009; 20:63-78.
8. Tobin NH, Learn GH, Holte SE, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79:9625-9634. (Pubitemid 41022306)
9. Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106:839-845.
10. Chun TW, Davey RT Jr, Ostrowski M, et al. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy. Nat Med 2000; 6:757-761. (Pubitemid 30469423)
11. Gardner MB, Carlos MP, Luciw PA. Simian retroviruses. In: Wormser GP, editor. AIDS and other manifestations of HIV infection, 4th ed New York: Raven Press, NY; 2004. pp. 195-262.
12. Van Rompay KK. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res 2010; 85:159-175.
13. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2- phosphonylmethoxypropyl)adenine. Science 1995; 270:1197-1199.
14. Van Rompay KK, Matthews TB, Higgins J, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184 V mutation in reverse transcriptase. J Virol 2002; 76:6083-6092. (Pubitemid 34556303)
15. Shen A, Zink MC, Mankowski JL, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003; 77:4938-4949. (Pubitemid 36402842)
16. Klatt NR, Shudo E, Ortiz AM, et al. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog 2010; 6:e1000747.
17. Wong JK, Strain MC, Porrata R, et al. In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog 2010; 6:e1000748.
18. Giuffre AC, Higgins J, Buckheit RW Jr, North TW. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother 2003; 47:1756-1759. (Pubitemid 36548569)
19. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virusinfected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
20. Lewis MG, Norelli S, Collins M, et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010; 7:21.
21. Zink MC, Brice AK, Kelly KM, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202:161-170.
22. Annamalai L, Bhaskar V, Pauley DR, et al. Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virusinfected and CD8+ lymphocyte-depleted rhesus macaques. Am J Pathol 2010; 177:777-791.
23. Marcondes MC, Flynn C, Huitron-Rezendiz S, et al. Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS 2009; 23:1187-1195.
24. Ratai EM, Bombardier JP, Joo CG, et al. Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS. PLoS One 2010; 5:e10523.
25. Balzarini J, Weeger M, Camarasa MJ, et al. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific nonnucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun 1995; 211:850-856.
26. Uberla K, Stahl-Hennig C, Bottiger D, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 1995; 92:8210-8214.
27. Soderberg K, Denekamp L, Nikiforow S, et al. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol 2002; 76:5803-5806. (Pubitemid 34517931)
28. North TW, Van Rompay KK, Higgins J, et al. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 2005; 79:7349-7354. (Pubitemid 40756770)
29. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
30. Hofman MJ, Higgins J, Matthews TB, et al. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:3483-3490. (Pubitemid 39129349)
31. Leutenegger CM, Higgins J, Matthews TB, et al. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res Hum Retroviruses 2001; 17:243-251. (Pubitemid 32113572)
32. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
33. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219. (Pubitemid 37204311)
34. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536. (Pubitemid 37259753)
35. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884. (Pubitemid 351723493)
36. Deere JD, Higgins J, Cannavo E, et al. Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One 2010; 5:e11640.
37. Jiang Y, Tian B, Saifuddin M, et al. RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther 2009; 6:23.
38. Ambrose Z, Boltz V, Palmer S, et al. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 2004; 78:13553-13561. (Pubitemid 39612755)
39. Ambrose Z, Palmer S, Boltz VF, et al. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 2007; 81:12145-12155. (Pubitemid 350085830)
40. Shao W, Kearney M, Maldarelli F, et al. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. Retrovirology 2009; 6:101.
41. Hatziioannou T, Ambrose Z, Chung NP, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A 2009; 106:4425-4429.